The DOI matches its Crossref record; 83 of the 83 references it cites were found in a registry or an index.
Poly(ethylene glycol)-Prodrug Conjugates: Concept, Design, and Applications
Open accessAbstract
Poly(ethylene glycol) (PEG) is the most widely used polymer in delivering anticancer drugs clinically. PEGylation (i.e., the covalent attachment of PEG) of peptides proteins, drugs, and bioactives is known to enhance the aqueous solubility of hydrophobic drugs, prolong circulation time, minimize nonspecific uptake, and achieve specific tumor targetability through the enhanced permeability and retention effect. Numerous PEG-based therapeutics have been developed, and several have received market approval. A vast amount of clinical experience has been gained which has helped to design PEG prodrug conjugates with improved therapeutic efficacy and reduced systemic toxicity. However, more efforts in designing PEG-based prodrug conjugates are anticipated. In light of this, the current paper highlights the synthetic advances in PEG prodrug conjugation methodologies with varied bioactive components of clinical relevance. In addition, this paper discusses FDA-approved PEGylated delivery systems, their intended clinical applications, and formulations under clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review
Maeda, H., Wu, J., Sawa, T., Matsumura, Y., & Hori, K. (2000) · Journal of Controlled Release · doi:10.1016/s0168-3659(99)00248-5 · Cited by 6,565
Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection
Fried, M. W., Shiffman, M. L., Reddy, K. R., Smith, C., Marinos, G., Gonçales, F. L., Häussinger, D., Diago, M., Carosi, G., Dhumeaux, D., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020047 · Cited by 6,389
Manns, M. P., McHutchison, J. G., Gordon, S. C., Rustgi, V. K., Shiffman, M., Reindollar, R., Goodman, Z. D., Koury, K., Ling, M.-H., & Albrecht, J. K. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06102-5 · Cited by 6,029
Poly(ethylene glycol) in Drug Delivery: Pros and Cons as Well as Potential Alternatives
Knop, K., Hoogenboom, R., Fischer, D., & Schubert, U. S. (2010) · Angewandte Chemie International Edition · doi:10.1002/anie.200902672 · Cited by 3,533
Effect of pegylation on pharmaceuticals
Harris, J. M., & Chess, R. B. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1033 · Cited by 3,431
The dawning era of polymer therapeutics
Duncan, R. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1088 · Cited by 3,269
Polymer conjugates as anticancer nanomedicines
Duncan, R. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1958 · Cited by 1,962
Gee, G. (1972) · Polymer · doi:10.1016/0032-3861(72)90025-0 · Cited by 1,360
Abuchowski, A., van Es, T., Palczuk, N. C., & Davis, F. F. (1977) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)40291-2 · Cited by 1,358
Abuchowski, A., McCoy, J. R., Palczuk, N. C., van Es, T., & Davis, F. F. (1977) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)40292-4 · Cited by 1,274
Peginterferon Alfa-2a in Patients with Chronic Hepatitis C
Zeuzem, S., Feinman, S. V., Rasenack, J., Heathcote, E. J., Lai, M.-Y., Gane, E., O'Grady, J., Reichen, J., Diago, M., Lin, A., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200012073432301 · Cited by 1,220
Polymer Therapeutics: Concepts and Applications
Haag, R., & Kratz, F. (2006) · Angewandte Chemie International Edition · doi:10.1002/anie.200502113 · Cited by 1,115
Structure and properties of pharmacologically active polymers
Ringsdorf, H. (1975) · Journal of Polymer Science: Polymer Symposia · doi:10.1002/polc.5070510111 · Cited by 1,094
Maeda, H., Sawa, T., & Konno, T. (2001) · Journal of Controlled Release · doi:10.1016/s0168-3659(01)00309-1 · Cited by 925
Kirkwood, J. M., Ibrahim, J. G., Sondak, V. K., Richards, J., Flaherty, L. E., Ernstoff, M. S., Smith, T. J., Rao, U., Steele, M., & Blum, R. H. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.12.2444 · Cited by 912
Treatment of Acromegaly with the Growth Hormone–Receptor Antagonist Pegvisomant
Trainer, P. J., Drake, W. M., Katznelson, L., Freda, P. U., Herman-Bonert, V., van der Lely, A. J., Dimaraki, E. V., Stewart, P. M., Friend, K. E., Vance, M. L., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200004203421604 · Cited by 879
Proceedings of the American Association for Cancer Research.
Konings, E. J. M., van den Brandt, P. A., Saris, W. H. M., Brants, H. A. M., & Goldbohm, R. A. (2001) · Cited by 764
Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist
van der Lely, A. J., Hutson, R. K., Trainer, P. J., Besser, G. M., Barkan, A. L., Katznelson, L., Klibanski, A., Herman-Bonert, V., Melmed, S., Vance, M. L., et al. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06844-1 · Cited by 645
FDA-approved poly(ethylene glycol)–protein conjugate drugs
Alconcel, S. N. S., Baas, A. S., & Maynard, H. D. (2011) · Polymer Chemistry · doi:10.1039/c1py00034a · Cited by 643
Eggermont, A. M., Suciu, S., Santinami, M., Testori, A., Kruit, W. H., Marsden, J., Punt, C. J., Salès, F., Gore, M., MacKie, R., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61033-8 · Cited by 640
Polymer–drug conjugates: Progress in polymeric prodrugs
Khandare, J., & Minko, T. (2006) · Progress in Polymer Science · doi:10.1016/j.progpolymsci.2005.09.004 · Cited by 639
Self-citationRational Design of Potent Antagonists to the Human Growth Hormone Receptor
Fuh, G., Cunningham, B. C., Fukunaga, R., Nagata, S., Goeddel, D. V., & Wells, J. A. (1992) · Science · doi:10.1126/science.256.5064.1677 · Cited by 631
Bailon, P., Palleroni, A., Schaffer, C. A., Spence, C. L., Fung, W.-J., Porter, J. E., Ehrlich, G. K., Pan, W., Xu, Z.-X., Modi, M. W., et al. (2001) · Bioconjugate Chemistry · doi:10.1021/bc000082g · Cited by 611
Greish, K. (2007) · Journal of Drug Targeting · doi:10.1080/10611860701539584 · Cited by 600
Filgrastim (r-metHuG-CSF): the first 10 years
Welte, K., Gabrilove, J., Bronchud, M., Platzer, E., & Morstyn, G. (1996) · Blood · doi:10.1182/blood.v88.6.1907.bloodjournal8861907 · Cited by 599
Green, M. D., Koelbl, H., Baselga, J., Galid, A., Guillem, V., Gascon, P., Siena, S., Lalisang, R. I., Samonigg, H., Clemens, M. R., et al. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg019 · Cited by 586
Chemistry of polyethylene glycol conjugates with biologically active molecules
Zalipsky, S. (1995) · Advanced Drug Delivery Reviews · doi:10.1016/0169-409x(95)00023-z · Cited by 552
Delivery of Therapeutic Proteins
Pisal, D. S., Kosloski, M. P., & Balu-Iyer, S. V. (2010) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22054 · Cited by 532
Vogel, C. L., Wojtukiewicz, M. Z., Carroll, R. R., Tjulandin, S. A., Barajas-Figueroa, L. J., Wiens, B. L., Neumann, T. A., & Schwartzberg, L. S. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.102 · Cited by 482
BROOME, J. D. (1961) · Nature · doi:10.1038/1911114a0 · Cited by 459
PEG conjugates in clinical development or use as anticancer agents: An overview
Pasut, G., & Veronese, F. M. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.02.010 · Cited by 457
Treatment of Adenosine Deaminase Deficiency with Polyethylene Glycol–Modified Adenosine Deaminase
Hershfield, M. S., Buckley, R. H., Greenberg, M. L., Melton, A. L., Schiff, R., Hatem, C., Kurtzberg, J., Markert, M. L., Kobayashi, R. H., Kobayashi, A. L., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198703053161005 · Cited by 443
Ganson, N. J., Kelly, S. J., Scarlett, E., Sundy, J. S., & Hershfield, M. S. (2005) · Arthritis Research & Therapy · doi:10.1186/ar1861 · Cited by 350
Tumor-specific targeting of an anticancer drug delivery system by LHRH peptide
Dharap, S. S., Wang, Y., Chandna, P., Khandare, J. J., Qiu, B., Gunaseelan, S., Sinko, P. J., Stein, S., Farmanfarmaian, A., & Minko, T. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0504274102 · Cited by 340
Self-citationSeymour, L. W., Miyamoto, Y., Maeda, H., Brereton, M., Strohalm, J., Ulbrich, K., & Duncan, R. (1995) · European Journal of Cancer · doi:10.1016/0959-8049(94)00514-6 · Cited by 337
PEGylated Proteins: Evaluation of Their Safety in the Absence of Definitive Metabolism Studies
Webster, R., Didier, E., Harris, P., Siegel, N., Stadler, J., Tilbury, L., & Smith, D. (2007) · Drug Metabolism and Disposition · doi:10.1124/dmd.106.012419 · Cited by 337
Dinndorf, P. A., Gootenberg, J., Cohen, M. H., Keegan, P., & Pazdur, R. (2007) · The Oncologist · doi:10.1634/theoncologist.12-8-991 · Cited by 324
Pegaspargase: a review of clinical studies
Graham, M. (2003) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(03)00110-8 · Cited by 322
Enzymatic Depletion of Tumor Hyaluronan Induces Antitumor Responses in Preclinical Animal Models
Thompson, C. B., Shepard, H. M., O'Connor, P. M., Kadhim, S., Jiang, P., Osgood, R. J., Bookbinder, L. H., Li, X., Sugarman, B. J., Connor, R. J., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0470 · Cited by 298
PEG-uricase in the management of treatment-resistant gout and hyperuricemia
Sherman, M. R., Saifer, M. G. P., & Perez-Ruiz, F. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.06.011 · Cited by 291
The Design and Development of Pegfilgrastim (PEG-rmetHuG-CSF, Neulasta®)
Molineux, G. (2004) · Current Pharmaceutical Design · doi:10.2174/1381612043452613 · Cited by 283
From good old biochemical analyses to high-throughput omics measurements and back
Heinemann, M., & Sauer, U. (2011) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2010.12.002 · Cited by 263
Polymer therapeutics as nanomedicines: new perspectives
Duncan, R. (2011) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2011.05.507 · Cited by 254
Kang, J. S., DeLuca, P. P., & Lee, K. C. (2009) · Expert Opinion on Emerging Drugs · doi:10.1517/14728210902907847 · Cited by 252
Use of peginterferon alfa-2a (40 KD) (Pegasys®) for the treatment of hepatitis C
Rajender Reddy, K., Modi, M. W., & Pedder, S. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00028-5 · Cited by 241
Biomedical and biotechnological applications of PEG- and PM-modified proteins
Inada, Y., Furukawa, M., Sasaki, H., Kodera, Y., Hiroto, M., Nishimura, H., & Matsushima, A. (1995) · Trends in Biotechnology · doi:10.1016/s0167-7799(00)88912-x · Cited by 225
Drug targeting to the colon with lectins and neoglycoconjugates
Minko, T. (2004) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2003.10.017 · Cited by 222
Sundy, J. S., Ganson, N. J., Kelly, S. J., Scarlett, E. L., Rehrig, C. D., Huang, W., & Hershfield, M. S. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22403 · Cited by 221
Macdougall, I. C., Robson, R., Opatrna, S., Liogier, X., Pannier, A., Jordan, P., Dougherty, F. C., & Reigner, B. (2006) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.00730306 · Cited by 189
Novel Prodrugs of SN38 Using Multiarm Poly(ethylene glycol) Linkers
Zhao, H., Rubio, B., Sapra, P., Wu, D., Reddy, P., Sai, P., Martinez, A., Gao, Y., Lozanguiez, Y., Longley, C., et al. (2008) · Bioconjugate Chemistry · doi:10.1021/bc700333s · Cited by 188
Asparaginase (native ASNase or pegylated ASNase) in the treatment of acute lymphoblastic leukemia.
Avramis, V. I., & Tiwari, P. (2006) · PubMed Central · Cited by 177
Molecular Targeting of Drug Delivery Systems to Cancer
Minko, T., Dharap, S., Pakunlu, R., & Wang, Y. (2004) · Current Drug Targets · doi:10.2174/1389450043345443 · Cited by 175
Molecular targeting of drug delivery systems to ovarian cancer by BH3 and LHRH peptides
Dharap, S. (2003) · Journal of Controlled Release · doi:10.1016/s0168-3659(03)00209-8 · Cited by 172
Bukowski, R. M., Tendler, C., Cutler, D., Rose, E., Laughlin, M. M., & Statkevich, P. (2002) · Cancer · doi:10.1002/cncr.10663 · Cited by 166
20-O-Acylcamptothecin Derivatives: Evidence for Lactone Stabilization
Zhao, H., Lee, C., Sai, P., Choe, Y. H., Boro, M., Pendri, A., Guan, S., & Greenwald, R. B. (2000) · The Journal of Organic Chemistry · doi:10.1021/jo000221n · Cited by 162
Antitumoral activity of PEG–gemcitabine prodrugs targeted by folic acid
Pasut, G., Canal, F., Dalla Via, L., Arpicco, S., Veronese, F. M., & Schiavon, O. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.02.002 · Cited by 160
Prodrugs : challenges and rewards
Stella, V. J. (2007) · Cited by 153
Novel strategies for stimulating erythropoiesis and potential new treatments for anaemia
Macdougall, I. C., & Eckardt, K. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69120-4 · Cited by 146
Killander, D., Dohlwitz, A., Engstedt, L., Franzén, S., Gahrton, G., GULLBRING, B., Holm, G., Holmgren, A., Höglund, S., KILLANDER, A., et al. (1976) · Cancer · Cited by 143
Releasable PEGylation of proteins with customized linkers
Filpula, D. R., & Zhao, H. (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.02.001 · Cited by 140
Structure-biocompatibility relationship of dendritic polyglycerol derivatives
Khandare, J. J., Mohr, A., Calderón, M., Welker, P., Licha, K., & Haag, R. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2010.02.001 · Cited by 122
Self-citationClinical pharmacology of polyethylene glycol-L-asparaginase.
Ho, D. H., Brown, N. S., Yen, A., Holmes, R., Keating, M. J., Abuchowski, A., Newman, R. A., & Krakoff, I. H. (1986) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)08348-5 · Cited by 119
Immunotherapy with monomethoxypolyethylene glycol modified allergens.
Dreborg, S. K. G., & Akerblom, E. B. (1990) · PubMed · Cited by 115
David, A., Kopečková, P., Minko, T., Rubinstein, A., & Kopec̆ek, J. (2003) · European Journal of Cancer · doi:10.1016/j.ejca.2003.07.001 · Cited by 113
Řı́hová, B., Etrych, T., Pechar, M., Jelínková, M., Šťastný, M., Hovorka, O., Kovář, M., & Ulbrich, K. (2001) · Journal of Controlled Release · doi:10.1016/s0168-3659(01)00320-0 · Cited by 106
Polymeric anticancer drugs with pH-controlled activation
Ulbrich, K., Etrych, T., Chytil, P., Pechar, M., Jelínková, M., & Rihova, B. (2004) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2003.02.001 · Cited by 103
PEG–Ara-C conjugates for controlled release
Schiavon, O., Pasut, G., Moro, S., Orsolini, P., Guiotto, A., & Veronese, F. M. (2004) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2003.10.005 · Cited by 95
Booth, C., Hershfield, M. S., Notarangelo, L. D., Buckley, R. H., Hoenig, M., Mahlaoui, N., Cavazzana, M., Aiuti, A., & Gaspar, H. B. (2007) · Clinical Immunology · doi:10.1016/j.clim.2006.12.009 · Cited by 91
Schlesinger, N., Yasothan, U., & Kirkpatrick, P. N. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3349 · Cited by 91
PEG-epirubicin Conjugates with High Drug Loading
Pasut, G., Scaramuzza, S., Schiavon, O., Mendichi, R., & Veronese, F. M. (2005) · Journal of Bioactive and Compatible Polymers · doi:10.1177/0883911505053377 · Cited by 87
Lipid-coated enzymes as efficient catalysts in organic media
Okahata, Y., & Mori, T. (1997) · Trends in biotechnology · doi:10.1016/s0167-7799(97)84203-5 · Cited by 86
Scott, L. C., Yao, J. C., Benson, A. B., Thomas, A., Falk, S. J., Mena, R. R., Picus, J., Wright, J. R., Mulcahy, M. F., Ajani, J. A., et al. (2008) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-008-0746-2 · Cited by 78
Bax, B. E., Bain, M. D., Fairbanks, L. D., et al. (2000) · British Journal of Haematology · doi:10.1046/j.1365-2141.2000.02059.x · Cited by 74
Pegvisomant in the treatment of acromegaly
Parkinson, C. (2003) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(03)00111-x · Cited by 42
Suppression of antibody responses by conjugates of antigens and monomethoxypoly(ethylene glycol)
Sehon, A. H. (1991) · Advanced Drug Delivery Reviews · doi:10.1016/0169-409x(91)90041-a · Cited by 41
Multimeric, Multifunctional Derivatives of Poly(ethylene glycol)
Zacchigna, M., Cateni, F., Drioli, S., & Bonora, G. M. (2011) · Polymers · doi:10.3390/polym3031076 · Cited by 38
Hertel, J., Locay, H. R., Scarlata, D., Jackson, L., Prathikanti, R., & Audhya, P. (2006) · American Journal of Nephrology · doi:10.1159/000092852 · Cited by 38
Synthesis of Tailor-Made Soluble Polymeric Drug Carriers
Kopec̆ek, J. (1984) · Springer eBooks · doi:10.1007/978-1-4613-2745-5_4 · Cited by 37
Agrawal, N. R., Bukowski, R. M., Rybicki, L. A., Kurtzberg, J., Cohen, L. J., & Hussein, M. A. (2003) · Cancer · doi:10.1002/cncr.11480 · Cited by 36
Lea, J. P., Norris, K. C., & Agodoa, L. Y. C. (2008) · American Journal of Nephrology · doi:10.1159/000127981 · Cited by 25
Macromolecular Prodrugs of Small Molecules
Marinaro, W. A., & Stella, V. J. (2008) · Springer eBooks · doi:10.1007/978-0-387-49785-3_27 · Cited by 9
Development of PEGylated mammalian urate oxidase as a therapy for patients with refractory gout
Hershfield, M. S., Sundy, J. S., Ganson, N. J., & Kelly, S. J. (2009) · Birkhäuser Basel eBooks · doi:10.1007/978-3-7643-8679-5_13 · Cited by 7
Proteins: Conjugation, Cross-Linking, and PEGylation
Hinds, K. D. (2016) · Taylor & Francis eBooks · doi:10.1081/e-ebpp-120052222 · Cited by 6
Cited by
Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy
Pérez-Herrero, E., & Fernández-Medarde, A. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2015.03.018 · Cited by 1,875
The expanding role of prodrugs in contemporary drug design and development
Rautio, J., Meanwell, N. A., Di, L., & Hageman, M. J. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.46 · Cited by 767
Turecek, P. L., Bossard, M. J., Schoetens, F., & Ivens, I. A. (2016) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2015.11.015 · Cited by 733
Srinivasarao, M., & Low, P. S. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00013 · Cited by 605
PEGylation in anti-cancer therapy: An overview
Mishra, P., Nayak, B., & Dey, R. K. (2016) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2015.08.011 · Cited by 382
Metadata
- Authors
- Banerjee, S. S., Aher, N., Patil, R., & Khandare, J.
- Venue
- Journal of Drug Delivery
- Publisher
- Wiley
- Published
- 2012-05-07
- Volume
- 2012
- Pages
- 1-17
- ISSN
- 2090-3014 (ISSN-L)
- 2090-3022
- OpenAlex
- W2073869665
- Cited by
- 282
- References
- 83
- FWCI
- 7.46
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.